InspireMD Inc (NYSEAMERICAN:NSPR) has erupted up +50% this week but has been unable to hold the gains. NSPR peaked over $2 mark about a year ago, so NSPR may have some room to grow and the news coming out is quite interesting.

NSPR is a leader in EPS technology or embolic prevention systems – which is essential for preventing strokes. NSPR just got their technology, the CGuard, approved in India. They also found a distributor for the platform as well.

InspireMD Inc (NYSEAMERICAN:NSPR) is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Furtheremore, NSPR seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.

NSPR intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.

Find out when $NSPR reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

Sanjiv Gandhi, Managing Director of Hester Diagnostics, commented, “We are excited to partner with InspireMD, given the extensive clinical data illustrating the safety advantages of CGuard™ EPS. We are now gearing up and look forward to commencing the formal commercial launch of the product.”

“The approval of CGuard™ EPS in India marks another commercial milestone as we continue to expand our global footprint,” said Agustin Gago, EVP and Chief Commercial Officer of InspireMD.  “We are excited to partner with Hester Diagnostics, which brings an impressive track record launching medical devices in India and to the key clinical specialties that treat carotid artery disease.”

InspireMD Inc (NYSEAMERICAN:NSPR) has a market cap of $2.23M and shares out at 7.47M. NSPR has another conference call upcoming, so we should learn more about this deal and the potential revenue going forward. Sign-up for continuing coverage on shares of $NSPR stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $NSPR, either long or short, and we have not been compensated for this article.